Literature DB >> 2569560

Outcome in newborn babies given anti-varicella-zoster immunoglobulin after perinatal maternal infection with varicella-zoster virus.

E Miller1, J E Cradock-Watson, M K Ridehalgh.   

Abstract

281 newborn babies whose mothers had chickenpox and 25 whose mothers had herpes zoster during the perinatal period were investigated. IgG antibody was present at birth in all babies born more than 7 days after the onset of maternal chickenpox. When the mother's rash appeared 7-3 days before delivery progressively fewer babies were born with antibody, and no infant born less than 3 days after the onset had antibody at birth. Infants were given 100 or 250 mg of anti-varicella-zoster immunoglobulin (VZIG) shortly after birth or the onset of post-natal maternal chickenpox. 1 infant died, without neonatal varicella. Of the 280 surviving infants 169 (60%) were infected--134 (48%) with chickenpox and 35 (13%) without clinical features. The clinical attack rate was highest (60%) in infants whose mothers had chickenpox between 7 days before and 7 days after delivery. Chickenpox was severe in 19 infants, 16 of whom were exposed to maternal chickenpox between 4 days before and 2 days after delivery. There was no evidence that a severe outcome was associated with transplacentally acquired infection. Perinatal maternal herpes zoster did not cause neonatal infection. VZIG should be given to infants at risk, including those whose mothers have chickenpox during the last 7 days of pregnancy.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2569560     DOI: 10.1016/s0140-6736(89)90547-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  22 in total

1.  Varicella zoster immune globulin use in neonates and infants.

Authors: 
Journal:  Can J Infect Dis       Date:  1996-01

Review 2.  [Skin infections in pregnancy].

Authors:  R R Müllegger; M Glatz
Journal:  Hautarzt       Date:  2010-12       Impact factor: 0.751

3.  An analysis of infection control of varicella-zoster virus infections in Addenbrooke's Hospital Cambridge over a 5-year period, 1987-92.

Authors:  T G Wreghitt; J Whipp; C Redpath; W Hollingworth
Journal:  Epidemiol Infect       Date:  1996-08       Impact factor: 2.451

4.  Chickenpox: an ageless disease.

Authors:  Annalan Mathew Dwight Navaratnam; Nan Ma; Maria Farrukh; Aza Abdulla
Journal:  BMJ Case Rep       Date:  2017-12-22

5.  Varicella zoster virus infection in pregnancy.

Authors:  D McIntosh; D Isaacs
Journal:  Arch Dis Child       Date:  1993-01       Impact factor: 3.791

6.  Chickenpox during pregnancy.

Authors:  G L Gilbert
Journal:  BMJ       Date:  1993-04-24

7.  Varicella zoster virus infection in pregnancy.

Authors:  E Miller
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1994-03       Impact factor: 5.747

8.  Neonatal varicella: A case report.

Authors:  Ak Bhardwaj; Pd Sharma; A Sharma
Journal:  Australas Med J       Date:  2011-06-30

Review 9.  Microbiology laboratory and the management of mother-child varicella-zoster virus infection.

Authors:  Massimo De Paschale; Pierangelo Clerici
Journal:  World J Virol       Date:  2016-08-12

Review 10.  Chickenpox.

Authors:  George H Swingler
Journal:  BMJ Clin Evid       Date:  2007-08-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.